Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | FABP4 | P15090 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3648553 | 0.83 | ESR2 (0.45) | ESR2NR1H2MKNK1ADORA1HPGDS | |
| SCHEMBL3799422 | 0.82 | ESR2 (0.44) | ESR2NR1H2MKNK1ADORA1HPGDS | |
| SCHEMBL952114 | 0.78 | ESR2 (0.45) | ESR2NR1H2MKNK1ADORA1PTGER4 | |
| SCHEMBL8247425 | 0.77 | NR1H2 (0.42) | ESR2NR1H2MAPT | |
| SCHEMBL3693556 | 0.76 | ESR2 (0.44) | ESR2NR1H2MKNK1ADORA1 | |
| SCHEMBL4219188 | 0.73 | MKNK1 (0.45) | ESR2NR1H2MKNK1HPGDSSMN1; SMN2 | |
| SCHEMBL951930 | 0.73 | ESR2 (0.44) | ESR2NR1H2ADORA1 | |
| SCHEMBL951850 | 0.72 | ESR2 (0.48) | ESR2NR1H2ADORA1 | |
| SCHEMBL1751534 | 0.70 | CREBBP (0.42) | ESR2NR1H2MAPT | |
| SCHEMBL8264160 | 0.70 | USP30 (0.47) | ESR2NR1H2ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | EHARA TAKERU | 2009-05-28 | — | — | US | disclosed |
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | EHARA TAKERU | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137566-A1 | Substituted Piperdines as Renin Inhibitors | REN, ACE, AGTR1 | TP53 4554/4885ESR2 2484/4885NR1H2 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.